Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. (2014)

First Author: Salloway S
Attributed to:  Further defining the genetic architecture of Alzheimer's disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa1304839

PubMed Identifier: 24450891

Publication URI: http://europepmc.org/abstract/MED/24450891

Type: Journal Article/Review

Volume: 370

Parent Publication: The New England journal of medicine

Issue: 4

ISSN: 0028-4793